Skip to main content

Advertisement

SpringerLink
Log in

Comments on the use of a single or multiple probeset approach for microarray-based analyses of routine molecular markers in breast cancer

  • Letter to the Editor
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S et al (2010) Guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med 134:e48–e72

    PubMed  CAS  Google Scholar 

  2. Fisher B, Redmond C, Brown A, Wickerham DL, Wolmark N, Allegra J et al (1983) Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. J Clin Oncol 1:227–241

    PubMed  CAS  Google Scholar 

  3. Rose C, Thorpe SM, Andersen KW, Pedersen BV, Mouridsen HT, Blichert-Toft M et al (1985) Beneficial effect of adjuvant tamoxifen therapy in primary breast cancer patients with high oestrogen receptor values. Lancet 1:16–19

    Article  PubMed  CAS  Google Scholar 

  4. Roepman P, Horlings HM, Krijgsman O, Kok M, Bueno-de-Mesquita JM, Bender R, Linn SC, Glas AM, van de Vijver MJ (2009) Microarray-based determination of estrogen receptor, progesterone receptor, and HER2 receptor status in breast cancer. Clin Cancer Res 15:7003–7011

    Article  PubMed  CAS  Google Scholar 

  5. Oh DS, Troester MA, Usary J, Hu Z, He X, Fan C, Wu J, Carey LA, Perou CM (2006) Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J Clin Oncol 24:1656–1664

    Article  PubMed  CAS  Google Scholar 

  6. Tebbit CL, Zhai J, Untch BR, Ellis MJ, Dressman HK, Bentley RC, Baker JA, Marcom PK, Nevins JR, Marks JR, Olson JA Jr (2009) Novel tumor sampling strategies to enable microarray gene expression signatures in breast cancer: a study to determine feasibility and reproducibility in the context of clinical care. Breast Cancer Res Treat 118:635–643

    Article  PubMed  CAS  Google Scholar 

  7. Pusztai L, Ayers M, Stec J, Clark E, Hess K, Stivers D, Damokosh A, Sneige N, Buchholz TA, Esteva FJ, Arun B, Cristofanilli M, Booser D, Rosales M, Valero V, Adams C, Hortobagyi GN, Symmans WF (2003) Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. Clin Cancer Res 9:2406–2407

    PubMed  CAS  Google Scholar 

  8. Gong Y, Yan K, Lin F, Anderson K, Sotiriou C, Andre F, Holmes FA, Valero V, Booser D, Pippen JE Jr, Vukelja S, Gomez H, Mejia J, Barajas LJ, Hess KR, Sneige N, Hortobagyi GN, Pusztai L, Symmans WF (2007) Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. Lancet Oncol 8:203–211

    Article  PubMed  CAS  Google Scholar 

  9. Karn T, Metzler D, Ruckhäberle E, Hanker L, Gätje R, Solbach C, Ahr A, Schmidt M, Holtrich U, Kaufmann M, Rody A (2010) Data driven derivation of cutoffs from a pool of 3,030 Affymetrix arrays to stratify distinct clinical types of breast cancer. Breast Cancer Res Treat 120:567–579

    Article  PubMed  Google Scholar 

  10. Risueño A, Fontanillo C, Dinger ME, De Las Rivas J (2010) GATExplorer: genomic and transcriptomic explorer; mapping expression probes to gene loci, transcripts, exons and ncRNAs. BMC Bioinform 11:221

    Article  Google Scholar 

  11. Dai M, Wang P, Boyd AD, Kostov G, Athey B, Jones EG, Bunney WE, Myers RM, Speed TP, Akil H, Watson SJ, Meng F (2005) Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res 33:e175

    Article  PubMed  Google Scholar 

  12. O’Connor S, Beriwal S, Dabbs DJ, Bhargava R (2010) Concordance between semiquantitative immunohistochemical assay and oncotype DX RT-PCR assay for estrogen and progesterone receptors. Appl Immunohist Mol Morphol 18:268–272

    Article  Google Scholar 

  13. De Cremoux P, Bieche I, Tran-Perennou C, Vignaud S, Boudou E, Asselain B, Lidereau R, Magdelénat H, Becette V, Sigal-Zafrani B, Spyratos F (2004) Inter-laboratory quality control for hormone-dependent gene expression in human breast tumors using real-time reverse transcription-polymerase chain reaction. Endocr Relat Cancer 11:489–495

    Article  PubMed  Google Scholar 

  14. Badve SS, Baehner FL, Gray RP, Childs BH, Maddala T, Liu ML, Rowley SC, Shak S, Perez EA, Shulman LJ, Martino S, Davidson NE, Sledge GW, Goldstein LJ, Sparano JA (2008) Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. J Clin Oncol 26:2473–2481

    Article  PubMed  Google Scholar 

  15. Pierga JY, Delaloge S, Espié M, Brain E, Sigal-Zafrani B, Mathieu MC, Bertheau P, Guinebretière JM, Spielmann M, Savignoni A, Marty M (2010) A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients. Breast Cancer Res Treat 122:429–437

    Article  PubMed  CAS  Google Scholar 

  16. Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, Mejia JA, Booser D, Theriault RL, Buzdar AU, Dempsey PJ, Rouzier R, Sneige N, Ross JS, Vidaurre T, Gómez HL, Hortobagyi GN, Pusztai LJ (2006) Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 24:4236–4244

    Article  PubMed  CAS  Google Scholar 

  17. de Cremoux P, Valet F, Gentien D, Lehmann-Che J, Scott V, Tran-Perennou C, Barbaroux C, Servant N, Vacher S, Sigal-Zafrani B, Mathieu MC, Bertheau P, Guinebretière JM, Asselain B, Marty M, Spyratos F (2011) Importance of pre-analytical steps for transcriptome and RT-qPCR analyses in the context of the phase II randomised multicentre trial REMAGUS02 of neoadjuvant chemotherapy in breast cancer patients. BMC Cancer 11:215

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The authors would like to thank Nicolas Servant and Marie-Eglantine Dujaric for their help in statistical analyses and the members of the Remagus02 group (S Delaloge, M Espié, S Giacchetti, E Brain, JY Pierga, B Sigal, M-C Mathieu, P Bertheau, J-M Guinebretière) for their contribution to this study. This study was supported by academic grants (PHRC AOM/2OO2/02117) and industrial grants from Pfizer inc., Roche, Sanofi-Aventis.ISRCTN10059974.

Conflict of interest

The authors declare that they have no competing interest.

Author information

Author notes

  1. Patricia de Cremoux

    Present address: University Paris Diderot, Sorbonne Paris Cité, 1, avenue Claude Vellefaux, 75475, Paris Cedex 10, France

Authors and Affiliations

  1. Laboratoire d’Oncogénétique, Institut Curie-Hôpital René Huguenin, 35 rue Dailly, 92210, St-cloud, France

    Frédérique Spyratos & Ivan Bièche

  2. Department of Biostatistics, Institut Curie, 26 rue d’Ulm, 75005, Paris, France

    Fabien Valet & Bernard Asselain

  3. Translational Research Laboratory, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805, Villejuif, France

    Véronique Scott

  4. Department of Biochemistry, Molecular Oncology Unit, AP-HP, Hospital Saint-Louis, 1, avenue Claude Vellefaux, 75475, Paris Cedex 10, France

    Jacqueline Lehmann-Che & Patricia de Cremoux

  5. University Paris Diderot, Sorbonne, 1, avenue Claude Vellefaux, 75475, Paris Cedex 10, France

    Jacqueline Lehmann-Che & Michel Marty

  6. Centre for Therapeutic Innovations in Oncology and Haematology, AP-HP, Hospital Saint-Louis, 1, avenue Claude Vellefaux, 75475, Paris Cedex 10, France

    Olivier Tembo & Michel Marty

  7. Institut Curie, Molecular Pharmacology Unit, 26 rue d’Ulm, 75005, Paris, France

    Patricia de Cremoux

Authors
  1. Frédérique Spyratos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fabien Valet
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ivan Bièche
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Véronique Scott
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jacqueline Lehmann-Che
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Bernard Asselain
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Olivier Tembo
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Michel Marty
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Patricia de Cremoux
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Frédérique Spyratos.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOC 80 kb)

Supplementary material 2 (DOC 70 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Spyratos, F., Valet, F., Bièche, I. et al. Comments on the use of a single or multiple probeset approach for microarray-based analyses of routine molecular markers in breast cancer. Breast Cancer Res Treat 134, 443–448 (2012). https://doi.org/10.1007/s10549-012-2042-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-012-2042-4

Keywords

Search

Navigation